Professor Jiang XIA(夏江教授)


location    Room 360 Science Centre

Phone No.    (852) 3943 6165

Fax No.     (852) 2603 5057


Research Group Webpage    Prof. Xia’s Research Group





1999 B.Sc. Nanjing University
2002 M.S. Nanjing University
2006 Ph.D. Stanford University



Since 2021.8 Professor, Department of Chemistry, 
Professor (by courtesy), School of Life Sciences, The Chinese University of Hong Kong
2015-2021 Associate Professor (by courtesy), School of Life Sciences, The Chinese University of Hong Kong
2015-2021 Associate Professor, Department of Chemistry, The Chinese University of Hong Kong
2009-2014 Assistant Professor, The Chinese University of Hong Kong
2007-2008 Research Associate, Howard Hughes Medical Institute
2007-2008 Postdoctoral scholar, California Institute of Technology


Research Interests

Chemical and synthetic biology

We are interested in the chemistry, biology, and engineering of protein, with focuses on the development of new protein reactions for chemical biological applications, protein assembly in synthetic biological applications, and exploring protein-based biomaterials as new therapies for diseases, such as infection and degeneration.

Chemical biology of protein reaction
Site-selective protein reactions (cysteine, tyrosine to lysine reactions); reactions of proteins, enzymes, antibodies to organelles ex vivo and in vivo

Synthetic biology of protein assembly
Multienzyme complexes, synthetic metabolon, and synthetic organelles; regulation of metabolic flux in prokaryotic and eukaryotic cells for better biosynthesis of carotenoids, artemisinin, cannabinoids, or amorphadiene, etc

Biomedical applications of protein-based biomaterials
Engineered exosomes for targeted therapy of cartilage and skin regeneration, and peptides or enzymes against bacterial infection


Recent Publications

For complete publication list, click here

 1 “On-Resin Ugi Reaction for C-Terminally Modified and Head-to-Tail Cyclized Antibacterial Peptides” So, W. H.; Bao, Y.; Chen, X.; Xia, J.* Organic Letters 2021,
2 “Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing” Duan, L.; Ouyang, K.; Wang, J.; Xu, L.; Xu, X.; Wen, C.; Xie, Y.; Liang, Y.*; Xia, J.* ChemBioChem 2021,
3 “Bacteriophage endolysins against gram-positive bacteria, an overview on the clinical development and recent advances on the delivery and formulation strategies” Ho, M. K. Y.; Zhang, P.; Chen, X.; Xia, J.*; Leung, S. S. Y.* Critical Reviews in Microbiology 2021, 1-24.
4 “Manganese Dioxide Nanozyme for Reactive Oxygen Therapy of Bacterial Infection and Wound Healing” Liu, L.; Wang, C.; Li, Y.; Qiu, L.; Zhou, S.; Cui, P.; Jiang, P.; Ni, X.; Liu, R.; Du, X.; Wang, J.; Xia, J.* Biomaterials Science, 2021, DOI: 10.1039/D1BM00683E.
5 “Membrane-Permeable Antibacterial Enzyme against Multidrug-Resistant Acinetobacter baumannii” Chen, X.; Liu, M.; Zhang, P.; Leung, S. S. Y.*; Xia, J.* ACS Infectious Diseases, 2021  doi: 10.1021/acsinfecdis.1c00222.
6 “Antimicrobial peptides towards clinical application: delivery and formulation” Wang, C.; Hong, T.; Cui, P.; Wang, J.*; Xia, J.* Advanced Drug Delivery Review, 2021, 175, 113818.
7 “Antibacterial photodynamic gold nanoparticles for skin infection” Lei, X.; Qiu, L.; Lan, M.; Du, X.; Zhou, S.; Cui, P.; Zheng, R.; Jiang, P.*; Wang, J.*; Xia, J.* ACS Applied Bio Materials 2021, 4, 3124–3132.
 8 “Gelatinase-responsive release of antibacterial photodynamic peptide against Staphylococcus aureus” Qiu, L.; Wang, C.; Lei, X.; Du, X.; Guo, Q.; Zhou, S.; Cui, P.; Hong, T.; Jiang, P.; Wang, J.*; Li, Y.*; Xia, J.* Biomaterial Sci. 2021, 9, 3433-3444.
 9 “3D printed gelatin/hydroxyapatite scaffolds for stem cell chondrogenic differentiation and articular cartilage repair” Huang, J.; Huang, Z.; Liang, Y.; Yuan, W.; Bian, L.; Duan, L.; Rong, Z.; Xiong, J.*; Wang, D.*; Xia, J.* Biomaterials Sci. 2021, 9, 2620.
 10 “Non-surgical osteoarthritis therapy, intra-articular drug delivery toward clinical applications” Liang Yujie, Xia, J.* J. Drug Targeting 2021, 1-16.
 11 “Engineering exosomes for targeted drug delivery” Liang, Y.; Duan, L.; Lu, J.; Xia, J.* Theranostics 2021, 11, 3183-3195.
 12 “Exosome-mediated delivery of gene vectors for gene therapy” Duan, L.; Xu, L.; Xu, X.; Qin, Z.; Zhou, X.; Xiao, Y.; Liang, Y.*; Xia, J.* Nanoscale 2021, 13, 1387-1397.
 13 “Exosome-mediated drug delivery for cell-free therapy of osteoarthritis” Duan, L*.; Xu, X.; Xu, L.; Chen, H.; Li, X.; Alahdal, M.; Xiao, Y.; Liang, Y.*; Xia, J.* Curr. Med. Chem. 2020, DOI: 10.2174/0929867327666201118161232.
 14 “Exosome-Mediated Delivery of Kartogenin for Chondrogenesis of Synovial Fluid-Derived Mesenchymal Stem Cells and Cartilage Regeneration” Xu, X.; Liang, Y.; Li, X.; Ouyang, K.; Wang, M.; Cao, T.; Li, W.; Liu, J.; Xiong, J.; Li, B.; Xia, J.*; Wang, D.*; Duan, L.* Biomaterials 2020, 269, 120539.
 15 “Antibacterial photodynamic peptides for staphylococcal skin infection” Lei, X.; Qiu, L.; Lan, M.; Du, X.; Zhou, S.; Cui, P.; Zheng, R.; Jiang, P.*; Wang, J.*; Xia, J.* Biomater. Sci. 2020, 8, 6695-6702.
 16 “Synthetic Multienzyme Complexes Assembled on Virus-like Particles for Cascade Biosynthesis In Cellulo” Wei, Q.; He, S.; Qu, J.; Xia, J.* Bioconjugate Chem. 2020, 31, 2413-2420.
 17 “Bacteriophage-derived Endolysins to Target Gram-Negative Bacteria” Lai, W. C. B.; Chen, X.; Ho, M. K. Y.; Xia, J.; Leung, S. S. Y. Int. J. Pharmaceutics 2020, 589, 119833
 18 “Mesenchymal Stem Cell-Derived Exosomes for Treatment of Autism Spectrum Disorder” Liang, Y.; Duan, L.; Xu, X.; Li, X.; Liu, M.; Chen, H.; Lu, J.*; Xia, J.* ACS Appl. Bio Mater. 2020, 3, 6384−6393.
 19 “Chondrocyte-Targeted MicroRNA Delivery by Engineered Exosomes toward a Cell-Free Osteoarthritis Therapy” Liang, Y.; Xu, X.; Li, X.; Xiong, J.; Li, B.; Duan, L.*; Wang, D.*; Xia, J.* ACS Appl. Mater. Interfaces 2020, 12, 36938–36947
 20 “Host–guest protein assembly for affinity purification of methyl-lysine proteomes” Li, L.; Liu, M.; Yue, L.; Wang, R.; Zhang, N.; Liang, Y.; Zhang, L.; Cheng, L.*; Xia, J.*; Wang, R.* Anal. Chem. 202092, 9322-9329.
 21 “Phase-separated multienzyme biosynthesis” Liu, M.; He, S.; Cheng, L.; Qu, J.; Xia, J.* Biomacromolecules, 2020, 21, 2391-2399.
 22 “Safeguarding intestine cells against enteropathogenic Escherichia coli by intracellular protein reaction, a preventive antibacterial mechanism” Qiu, J.; Nie, Y.; Zhao, Y.; Zhang, Y.; Li, L.; Wang, R.; Wang, M.; Chen, S.; Wang, J.*; Li, Y.Q.*; Xia, J.* Proc. Natl. Acad. Sci. U. S. A. 2020, 117, 5260-5268.
 23 “On-Resin Passerini Reaction towards C-Terminal Photocaged Peptides” So, W. H.; Xia, J.* Organic Lett. 2020, 22, 214-218.
 24 “Self-Assembled Multi-Enzyme Nanostructures on Synthetic Protein Scaffolds” Liu, Z.; Cao, S.; Liu, M.; Kang, W.; Xia, J.*. ACS Nano 2019, 13, 11343-11352.
 25 “Modular enzyme assembly for enhanced cascade biocatalysis and metabolic flux” Kang, W.; Ma, T.; Liu, M.; Qu, J.; Liu, Z.; Zhang, H.; Shi, B.; Fu, S.; Ma, J.; Lai, L.; He, S.; Qu, J.; Au, S. W-N.; Kang, B. H.; Lau, W. C. Y.; Deng, Z.; Xia, J.*, Liu, T.*. Nat. Commun. 2019, 10, 4248.
 26 “Synthetic Multienzyme Complexes, Catalytic Nanomachineries for Cascade Biosynthesis In Vivo.” Qu, J., Cao, S., Wei, Q., Zhang, H., Wang, R., Kang, W., Ma, T., Zhang, L., Liu, T., Au, W-N. S., Sun, F., Xia, J.* ACS Nano 2019, 13, 9895-9906.
 27 “Site-selective lysine reactions guided by protein-peptide interaction” Zhang, Y.; Liang, Y.; Huang, F.; Zhang, Y.; Li, X.; Xia, J.* Biochemistry 2019, 58, 1010-1018. 
 28 “Affinity purification of methyllysine proteome by site-specific covalent conjugation” Wang, R.; Huang, M.; Li, L.; Kaneko, T.; Voss, C.; Zhang, L.*; Xia, J.*; Li, S. S. C.* Anal. Chem. 2018, 90, 13876-13881. 
 29 “Reverse binding mode of phosphotyrosine peptides with SH2 protein” Wang, R.; Leung, P. Y. M.; Huang, F.; Tang, Q.; Kaneko, T.; Huang, M.; Li, Z.; Li, S. S. C.*; Wang, Y.*; Xia, J.* Biochemistry 2018, 57, 5257-5269.
 30 “Syntenin-targeted peptide blocker inhibits progression of cancer cells” Liu, J.; Qu, J.; Zhou, W.; Huang, Y.; Jia, L.; Huang, X.; Qian, Z.; Xia, J.*; Yu. Y.* Eur. J. Med. Chem. 2018, 154, 354-366. 
 31 “Versatile site-selective protein reaction guided by WW domain–peptide motif interaction” Liu, M.; Ji, Z.; Zhang, M.; Xia, J.* Bioconjugate Chem., 2017, 28, 2199-2205.
 32 “Site-selective covalent reactions on proteinogenic amino acids” So, W. H.; Zhang, Y.; Kang, W.; Wong, C. T. T.*; Sun, H.*; Xia, J.* Curr. Opin. Biotech. 2017, 48, 220–227.
 33 “Targeted Covalent Inhibition of Grb2–Sos1 Interaction through Proximity-Induced Conjugation in Breast Cancer Cells”  Yu, Y.; Nie, Y.; Feng, Q.; Qu, J.; Wang, R.; Bian, L.; Xia, J.* Mol. Pharmaceutics 2017, 14, 1548−1557. 
 34 “Thiol-ether Stabilized DProline-LProline Induced b-Hairpin Peptide of Defensin Segment Increases its Anti-Candida Albicans Ability” Zhao, B.; Yang, D.; Wong, J. H.; Wang, J.; Yin, C.; Zhu, Y.; Fan, S.; Ng, T. B.*; Xia, J*.; Li, Z.* Chembiochem 2016, 17, 1416 – 1420. 
 35 “Affinity-guided protein conjugation: the trilogy of covalent protein labeling, assembly and inhibition” Yu, Y.; Xia, J.* Sci. China Chem. 2016, 59, 1-8 (Invited review)
 36 “PDZ-reactive peptide activates ephrin-B reverse signaling and inhibits neuronal chemotaxis” Yu, Y.; Liu, M.; Ng, T. T.; Huang, F.; Nie, Y.; Wang, R.; Yao, Z-P.; Li, Z.; Xia, J.* ACS Chem. Biol. 2016, 11, 149-158.   


Recent Grants

1. ITF TCFS, 1/8/2022 – 31/7/2024, PI
     Title: Engineering Exosomes for Tissue Regeneration and Osteoarthritis Treatment
           ITC GHP/074/20SZ: HK$1,350,000 
           Shenzhen Kaimao Biotechnology Co. Ltd.: HK$150,000
           PH-ITF: PiH/283/22 HK$804,000
           PH-ITF: PiH/284/22 HK$804,000
2. RGC GRF 22/23, 14306222, 1/1/2023– 31/12/2025, HK$ 870,000, PI
     Title: Chemoenzymatic tyrosine reactions for covalent protein labeling and exosome tracking
3. RGC GRF 21/22, 14304921, 1/1/2022 – 31/12/2024, HK$ 624,615, PI
     Title: Phase-separated multienzyme biosynthesis in vitro and in cellulo
4. RGC GRF 20/21, 14304320, 1/1/2021 – 31/12/2023, HK$ 666,512, PI
     Title: Site-Specific Acetylation of Immunoglobulin G, for Covalent Construction of Therapeutic Antibody Conjugates
5. Research Sustainability of Major RGC Funding Schemes (RSFS), 4930971, CUHK Faculty of Medicine. 3/6/2019 – 2/12/2020. HK$ 625,000. PI
     Title: Stem Cell-Based Chemical Biology Approach to Cartilage Repair
6. ITF TCFS, 1/2/2020 – 31/1/2022, PI (total 3,931,244.81 HKD)
     Title: Efficient Enzymatic Production of Diacylglycerol
           ITC GHP/060/18GD: HK$ 1,620,000 
           Shenzhen WWHS Ltd.: HK$180,000
           PH-ITF: PiH/395/19: HK$ 801,782.75
           PH-ITF: PiH/396/19: HK$ 801,782.75
           InP/459/19, ITC: HK$ 527,679.31
           PH-ITF: PiH/321/20: HK$539,360
           PH-ITF: InP/334/20: HK$ 299,961.29.
7. NSFC/RGC 18/19, N_CUHK422/18, 1/1/2019-31/12/2022, HK$ 1,120,056, PI
     Title: Hybrid Antimicrobial Peptide-Nylon-3 Polymers to Treat Infection in the Brain
8. Collaborative grant from industry, TJ1914536, 1/3/2020 – 28/2/2025, HK$ 1,500,00, PI
     Title: Recombinant collagen biomaterials
     Grant source: Jiangsu Unicollagen Biomedicine Co., Ltd.